EMBARGOED FOR RELEASE UNTIL 4 PM ET, December 17, 2014
AAN Calls for More Research on Medical Marijuana for Brain Diseases
MINNEAPOLIS -
The (AAN) is calling for more research on the use of medical marijuana for brain, spine and nervous system disorders in a new position statement released by the AAN, the world鈥檚 largest association of neurologists with more than 28,000 members. 鈥淭he current medical marijuana legislation being passed by policymakers across the country, which promotes marijuana-based products as treatment options for various brain and nervous system disorders, is not supported by high-level medical research,鈥 said position statement author Anup Patel, MD, with Nationwide Children鈥檚 Hospital in Columbus, Ohio, and a member of the AAN. 鈥淭here may be some safety concerns for marijuana-based products, especially for long-term use in patients with these diseases, as to date it has not been well-studied.鈥 The AAN supports the reclassification of marijuana-based products by the federal government from their current status as a Schedule I drug to improve access for study of marijuana or cannabinoids under approved research protocols. The AAN does not advocate for the legalization of marijuana-based products for use in brain and nervous system disorders at this time, Patel stated, as further research is needed to determine the benefits and safety of such products. This is especially important in the cases of people with underlying brain disorders and in children whose developing brains may be more vulnerable to the toxic effects of marijuana, according to the position statement. 鈥淲e recognize that there may be potential use for these agents in the treatment of some brain and nervous system disorders, but there is not sufficient evidence to make any definitive conclusions regarding the effectiveness of marijuana-based products for many neurologic conditions at this time,鈥 Patel said. In March 2014, the AAN published a on complementary alternative therapies, such as medical marijuana, to treat multiple sclerosis (MS). In April 2014, the AAN published a on the efficacy and safety of medical marijuana in selected brain and nervous system disorders, such as epilepsy, Parkinson鈥檚 disease, MS and Tourette syndrome. The position statement also notes that many cannabis preparations used in studies are not available in the United States. 鈥淚t is not appropriate to extrapolate the results of trials of standardized preparations to other, non-standardized, non-regulated cannabis products that may be commercially available in states with laws supporting the use of medical marijuana,鈥 Patel said. The position statement is available at